DelveInsight’s, “NK Cell Therapy Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the NK Cell Therapy Pipeline. Dive into DelveInsight’s comprehensive report today! @ NK Cell Therapy Pipeline Outlook

 

Key Takeaways from the NK Cell Therapy Pipeline Report

• June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
• DelveInsight’s NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
• The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
• Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

 

Stay ahead with the most recent pipeline outlook for NK Cell Therapy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ NK Cell Therapy Treatment Drugs

 

NK Cell Therapy Emerging Drugs Profile

• NKTR-214: Nektar therapeutics

• Monalizumab: Innate Pharma

• Bemarituzumab: Five Prime Therapeutics

• ALT 803: ImmunityBio

• CellProtect: XNK Therapeutics

• K-NK002: Kiadis Pharma

• NK-92: ImmunityBio

• WU-NK-101: Wugen

• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics

• ALECSAT: CytoVac

 

NK Cell Therapy Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

 

Explore groundbreaking therapies and clinical trials in the NK Cell Therapy Pipeline. Access DelveInsight’s detailed report now! @ New NK Cell Therapy Drugs

 

DelveInsight’s NK Cell Therapy pipeline report covers around 185+ products under different phases of clinical development like

• Late-stage products (Phase III and

• Mid-stage products (Phase II and

• Early-stage products (Phase I/II and Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravaginal

• Oral

• Parenteral

• Subcutaneous

• Topical.

• Molecule Type

 

NK Cell Therapy Pipeline Products have been categorized under various Molecule types such as

• Vaccines

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Product Type

 

 

Unveil the future of NK Cell Therapy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ NK Cell Therapy Market Drivers and Barriers

 

Scope of the NK Cell Therapy Pipeline Report

• Coverage- Global

• NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.

• NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

 

Get the latest on NK Cell Therapy Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NK Cell Therapy Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction

2. Executive Summary

3. Natural Killer (NK) cell therapy: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Late Stage Products (Phase III)

7. NKTR-214: Nektar therapeutics

8. Drug profiles in the detailed report…..

9. Mid Stage Products (Phase II)

10. CellProtect: XNK Therapeutics

11. Drug profiles in the detailed report…..

12. Early stage products (Phase I/II)

13. Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics

14. Drug profiles in the detailed report…..

15. Inactive Products

16. Natural Killer (NK) cell therapy Key Companies

17. Natural Killer (NK) cell therapy Key Products

18. Natural Killer (NK) cell therapy- Unmet Needs

19. Natural Killer (NK) cell therapy- Market Drivers and Barriers

20. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion

21. Natural Killer (NK) cell therapy Analyst Views

22. Natural Killer (NK) cell therapy Key Companies

23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/